Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 6/20 | 0.32 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812152 | 0.86 | NOS3 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL623786 | 0.84 | NOS3 (0.33) | NOS3NOS1NOS2CA1CA2 | |
| Water SCHEMBL21810558 | 0.84 | NOS3 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL3368527 | 0.83 | NOS3 (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL5345186 | 0.82 | CA1 (0.36) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL1883327 | 0.81 | NOS3 (0.36) | NOS3NOS1NOS2ITGB3ITGA2B | |
| SCHEMBL21404061 | 0.80 | CA1 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL941222 | 0.80 | ALDH1A1 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL1286967 | 0.79 | NOS3 (0.37) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL4281967 | 0.79 | NOS3 (0.40) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806328-B2 | Metabolic therapy for wound healing | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-11-07 | — | — | US | claimed |
| US-20210093602-A1 | METABOLIC THERAPY FOR WOUND HEALING | UNIVERSITY OF SOUTH FLORIDA | 2021-04-01 | — | — | US | claimed |
| US-10864184-B1 | Metabolic therapy for wound healing | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-12-15 | — | — | US | claimed |
| US-20200268701-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIV SOUTH FLORIDA (US) | 2020-08-27 | — | — | US | claimed |
| US-10646462-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-05-12 | — | — | US | claimed |
| US-20190313682-A1 | COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET | Metabolic Recovery Systems, LLC | 2019-10-17 | — | — | US | claimed |
| WO-2019200132-A1 | COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET | Metabolic Recovery Systems, LLC (US) | 2019-10-17 | — | — | WO | claimed |
| EP-2976073-B1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIV SOUTH FLORIDA (US) | 2019-08-28 | — | — | EP | claimed |
| US-20180021281-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | SCIADONICS, INC. | 2018-01-25 | — | — | US | claimed |
| WO-2018017667-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | SCIADONICS, INC. (US) | 2018-01-25 | — | — | WO | claimed |
| US-20160067207-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-03-10 | — | — | US | claimed |
| EP-2976073-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | University Of South Florida (US) | 2016-01-27 | — | — | EP | claimed |
| US-9138420-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-09-22 | — | — | US | claimed |
| US-20140350105-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-11-27 | — | — | US | claimed |
| WO-2014153416-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-09-25 | — | — | WO | claimed |
| EP-2567705-A2 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | Avicena Group, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | UNIVERSITY OF CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2006-10-26 | — | — | US | claimed |
| EP-1567180-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | Avicena Group, Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | CINCINNATI, UNIVERSITY OF | 2004-07-01 | — | — | US | claimed |
| WO-2003101402-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | AVICENA GROUP, INC. (US) | 2003-12-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | NOS3 728/4885NOS1 822/4885NOS2 694/4885 |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | NOS3 728/4885NOS1 822/4885NOS2 694/4885 |
| US-20180021281-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | FAAH, ELOVL1, DGKA | NOS3 1912/4885NOS1 1767/4885NOS2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.